This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D69.1 | Synonyms: Glanzmann thrombasthenia, GT, platelet GPIIb/IIIa deficiency
Hereditary thrombasthenia became known in 1918 when the Swiss pediatrician Eduard Glanzmann first described pediatric patients who had normal platelet counts but a severe bleeding tendency. Glanzmann named this condition 'thrombasthenia' (platelet weakness) and clinically observed that abnormal platelet aggregation function was the main pathophysiology.
As research on platelet membrane glycoproteins became active in the 1960s~1970s, in 1975 Nurden and Caen discovered that certain glycoprotein components were deficient in the platelets of patients with Glanzmann thrombasthenia. Subsequently, through the 1985~1990s, the protein was confirmed to be a heterodimeric receptor complex composed of glycoproteins GPIIb (CD41) and GPIIIa (CD61), and this complex was shown to function as the receptor for adhesive proteins such as fibrinogen (integrin αIIbβ3).
From the 1990s, mutations in the ITGA2B (GPIIb) and ITGB3 (GPIIIa) genes began to be identified. The disease is classified by expression pattern into Type I (GPIIb/IIIa complex below 5%), Type II (5~20%), and Type III (variant type, functional defect). With advances in molecular diagnostic techniques, more than 200 mutations have been reported to date.
In Korea, as molecular genetic diagnosis became available from the late 1990s, the genotypes of Korean patients began to be analyzed. It is recognized as a rare autosomal recessive bleeding disorder with a family history and is included in the rare disease registration program.
The fundamental cause of hereditary thrombasthenia is a quantitative deficiency or qualitative dysfunction of the platelet surface glycoprotein complex GPIIb (αIIb, CD41)/GPIIIa (β3, CD61), that is, integrin αIIbβ3. Upon platelet activation, this complex undergoes a conformational change and binds adhesive proteins such as fibrinogen, fibronectin, von Willebrand factor (vWF), and vitronectin, mediating platelet aggregation.
The cause is loss-of-function mutations in the ITGA2B (17q21.31, encoding GPIIb) or ITGB3 (17q21.32, encoding GPIIIa) gene. Various types of mutations are reported, including deletions, point mutations (missense, nonsense), splicing variants, and insertions. The two genes are located adjacent to each other and are under shared transcriptional regulation.
Glanzmann thrombasthenia has a high prevalence in populations with frequent consanguineous marriage (Bedouins of the Arabian Peninsula, certain tribes in India, the French Gypsy population, etc.). It is caused by homozygous or compound heterozygous mutations, and heterozygous carriers are clinically normal.
Hereditary thrombasthenia (Glanzmann thrombasthenia) follows an autosomal recessive mode of inheritance. The causative genes ITGA2B and ITGB3 are both located on the long arm of chromosome 17 (17q21.31-q21.32), adjacent to each other about 260 kb apart.
| Type | GPIIb/IIIa expression | Clinical features |
|---|---|---|
| Type I | Less than 5% of normal | Most severe, life-threatening bleeding possible |
| Type II | 5~20% of normal | Moderate bleeding tendency |
| Type III (variant type) | Normal range or above | Normal expression level but dysfunctional |
To date, more than 200 mutations have been identified in ITGA2B and ITGB3. Founder mutations exist in some populations. For example, ITGA2B c.1544+1G>A in Iraqi Jews, ITGB3 L117W in French Gypsies, and various deletions/point mutations in the Arab world are observed at specifically high frequencies.
Hereditary thrombasthenia (Glanzmann thrombasthenia) is an ultra-rare disease, with an estimated worldwide prevalence of about 1 in 1 million. However, prevalence is markedly higher in certain populations where consanguineous marriage is common. For example, it is reported at about 1/50,000 in Iraqi Jews and about 1/10,000~1/5,000 in Arab Bedouins.
In Korea, hereditary thrombasthenia is classified as an extremely rare disease. Reported cases in Korea are few, and accurate epidemiological data are lacking. The number of patients registered in the integrated rare disease registration system is estimated to be in the tens.
Because inheritance is autosomal recessive, males and females are equally affected. Bleeding symptoms usually appear from infancy, and some cases are diagnosed at menarche. Most are first diagnosed in childhood.
Normally, upon vascular injury, platelets adhere to exposed collagen or vWF (primary thrombus), and when platelets are activated, the GPIIb/IIIa complex (integrin αIIbβ3) converts to its active form. Activated αIIbβ3 binds to the RGD or KQAGDV sequences of fibrinogen, vWF, and fibronectin, inducing platelet aggregation through formation of bridges between platelets.
In hereditary thrombasthenia, when the GPIIb/IIIa complex is deficient or dysfunctional, fibrinogen binding and platelet aggregation do not occur even after platelet activation. Platelet shape change and granule release may occur normally, but the aggregation step is blocked. As a result, a platelet plug cannot form and hemostasis is not achieved.
In hereditary thrombasthenia, platelet count, platelet size, and initial platelet adhesion are generally normal. The GPIb-IX-V complex (vWF receptor) retains normal function, so the primary adhesion response is intact. In other words, a selective defect of platelet aggregation is the core pathophysiology.
The bleeding tendency of hereditary thrombasthenia is characterized by mucosal bleeding due to impaired platelet aggregation. Purpura and petechiae are uncommon, and bleeding from the mucosa (nose, oral cavity, gastrointestinal tract, uterus) predominates. Bleeding is excessive even in response to stimuli such as minor trauma, surgery, tooth extraction, and menstruation.
Type I patients show the most severe bleeding tendency and have a high likelihood of life-threatening bleeding. Type II shows a moderate bleeding tendency, and Type III is relatively mild but still shows clinically significant bleeding.
On physical examination, petechiae and purpura are typically not seen, unlike in thrombocytopenia. Traces of mucosal bleeding (nasal cavity, oral cavity), pallor due to iron deficiency anemia, and signs of anemia due to repeated bleeding may be observed.
| Test item | Result |
|---|---|
| Platelet count | Normal (150,000~400,000/μL) |
| Bleeding time | Markedly prolonged (>20 minutes) |
| Platelet aggregation tests (ADP, collagen, epinephrine) | Absent or markedly reduced aggregation response |
| Ristocetin-induced aggregation | Normal |
| Flow cytometry CD41/CD61 | Markedly reduced or absent |
| PT, aPTT | Normal |
On peripheral blood smear and electron microscopy, platelet size and morphology are normal. Alpha granules and dense granules are present normally within platelets.
It should be suspected in patients with a markedly prolonged bleeding time despite a normal platelet count, or in patients with abnormal platelet aggregation showing no response to multiple agonists such as ADP and collagen. Taking a family history is important, and confirming an autosomal recessive inheritance pattern helps screening.
On the platelet function analyzer (PFA-100/PFA-200), the closure time is markedly prolonged with both the collagen/ADP and collagen/epinephrine cartridges. Light transmission aggregometry (LTA) is the standard confirmatory test and shows absent aggregation induced by ADP, collagen, epinephrine, and arachidonic acid.
Screening should be performed with priority in families with consanguineous parents, when a family member has thrombasthenia, and in children with recurrent mucosal bleeding.
On light transmission aggregometry (LTA), the aggregation responses to ADP (5~10 μM), epinephrine (10 μM), collagen (2~5 μg/mL), arachidonic acid (1 mM), and thrombin receptor-activating peptide (TRAP) are absent or markedly reduced. Aggregation by ristocetin (1.2~1.5 mg/mL) (GPIb-mediated) is normal. This aggregation pattern is characteristic of Glanzmann thrombasthenia.
Flow cytometry using anti-CD41 (GPIIb) and anti-CD61 (GPIIIa) antibodies quantifies the expression of the GPIIb/IIIa complex on the platelet surface. Expression of <5% is found in Type I, 5~20% in Type II, and >20% in Type III.
Mutations are identified by Sanger sequencing or next-generation sequencing (NGS) of the ITGA2B and ITGB3 genes. Multiplex ligation-dependent probe amplification (MLPA) detects deletion/duplication variants. Molecular diagnosis is essential for confirming the diagnosis in patients and for carrier testing of family members.
For epistaxis, nasal compression, topical hemostatic agents (tranexamic acid nasal spray, gelatin sponge), and electrocautery are performed. For oral bleeding, a tranexamic acid mouthwash solution is used. When iron deficiency anemia is present, iron and folic acid supplementation is given.
Tranexamic acid is widely used for preoperative prophylaxis and for treatment during bleeding. Aminocaproic acid can also be used as an alternative. Prophylactic use is recommended before mucosal bleeding, tooth extraction, and minor surgery.
In some patients, particularly Type II or Type III, intravenous or intranasal administration of desmopressin (DDAVP) may temporarily reduce the bleeding tendency. However, its effect is limited in Type I.
For acute severe bleeding or surgery, transfusion of HLA- and platelet-specific antigen-matched platelets is needed. With repeated transfusions, there is a risk of developing alloantibodies against GPIIb/IIIa, which can cause transfusion refractoriness.
In patients who have become refractory to platelet transfusion because of antibody formation, recombinant FVIIa (NovoSeven) provides a hemostatic effect. It is approved for use in major bleeding or surgery and is also available for rare disease patients in Korea.
Hematopoietic stem cell transplantation is considered in cases of severe recurrent bleeding, transfusion refractoriness due to antibody formation, or no response to rFVIIa. Cures through allogeneic HSCT have been reported, but careful selection of indications is needed in view of transplant-related morbidity and mortality.
With appropriate management, most patients with hereditary thrombasthenia can maintain a near-normal lifespan. However, there is a risk of death when severe bleeding (intracranial hemorrhage, massive gastrointestinal bleeding) occurs. The bleeding tendency does not disappear with age, but in some patients the frequency of epistaxis tends to decrease in adulthood.
Type I patients have higher bleeding frequency and severity than Type II and III. Whether alloantibodies develop is important for long-term prognosis. Access to modern treatments such as tranexamic acid and rFVIIa has greatly improved prognosis.
Quality of life may be reduced by repeated bleeding episodes, transfusion dependence, and lifestyle restrictions (no contact sports, avoidance of aspirin and NSAIDs). Psychosocial support and patient education are important.
Medications that impair platelet function, such as aspirin, NSAIDs, and clopidogrel, should be avoided. Contact sports and strenuous activities are restricted to prevent trauma. Before surgery, tooth extraction, or procedures, a hemostasis plan must be established in consultation with the dedicated hematologist.
When there is an affected patient in the family, carrier status is determined through genetic counseling. In high-risk couples (both partners carriers), prenatal genetic testing (CVS, amniocentesis) or preimplantation genetic testing (PGT-M) is available. Genetic counseling is particularly emphasized in populations where consanguineous marriage is common.
It is important to educate patients and caregivers on recognizing signs of bleeding, emergency contacts, and medications available in emergencies (tranexamic acid, rFVIIa). The patient's diagnostic information should be shared with medical institutions in advance to enable prompt treatment in emergencies.